Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Tumor response, OS, and PFS. A and B, A summary of (A) best reduction and (B) percent change from baseline in the sum of the diameters of target tumors in each patient with NSCLC treated with nivolumab. C and D, A summary of (C) best reduction and (D) percent change from baseline in the sum of the diameters of target tumors in each patient with gastric cancer (GC) treated with nivolumab. E and F, A summary of the probability of OS in patients with (E) NSCLC and (F) GC. G and H, A summary of the probability of PFS in patients with (G) NSCLC and (H) GC. The 95% CI was determined by the Brookmeyer–Crowley method with log–log transformation. Circles indicate censoring. CR, complete response; SD, stable disease.